References
- Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132(1):66–75.
- D'Haens G, Sandborn WJ, Feagan, B, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132(2):763–786.
- Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009. Epub ahead of print.
- Lichtenstein GR, Kamm, MA, Boddu P, et al. Effect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5(1):95–102.
- Hanauer SB, Lichtenstein GR, Kamm MA, et al. MMX mesalamine for induction and maintenance therapy in mild-to-moderate ulcerative colitis. Gastroenterol Hepatol. 2009; 5(7):494–500.
- Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7(7):762–769.
- Kruis W, Kiudelis G, Racz I, et al; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009; 58(2):233–240.
- Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003; 1(3): 170–173.
- Kane S, Holderman W, Jacques P, et al. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preference and Adherence. 2008; 2:253–258.
- Magowan S, Kane S, Lange J. 5-ASA prescription refill rates of ulcerative colitis are independent of formulation and dosing regiments. Am J Gastroenterology. 2006; 101:S447. Abstract 1144.
- Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009; 29:855–862.
- Kane SV, Sumner M, Solomon DM, et al. Twelve-month persistence with 5-Aminosalicylic Acid Therapy: Results from a Large Pharmacy Database. Gastroenterology. 2009; 136:A 176. Abstract S1043.
- Kane SV, Sumner M, Solomon DM, et al. Continuing persistence with mesalamine therapy: Results from patients with long-term therapy. Am J Gastroenterol. 2009; 104:S475. Abstract 1271.
- Sandborn WJ, Balan G, Kuzmak B, Hanauer SB. Comparable pharmacokinetics of two delayed release formulations of oral mesalamine. Am J Gastroenterol. 2007; 102:S465. Abstract 944.